As a follow-up to our initial comment, Redeye updates its estimates and valuation model following yesterday's bolt-on acquisition of KPL ApS. The incorporation has a limited near-term financial impact but adds another meaningful growth avenue over the medium to longer term, further broadening Genovis' enzyme platform into recombinant proteases for LC-MS-based proteomics.
LÄS MER
